Prima Biomed (PBMD) Stock Nearly Quardruples in Value on Positive Clinical Study Results

NEW YORK (TheStreet) -- Prima Biomed shares are up 270% to $5.93 in afternoon trading on Wednesday after the biopharmaceutical company announced the final test data from the Phase II study of its ovarian cancer treatment.The tests showed that its cancer treatment CVac showed a trend for a clinically meaningful improvement in the overall survival rate over standard of care in second remission patients."This final clinical data for CVac is most encouraging for cancer patients in second remission...